The fibrin-derived citrullinated peptide β60-74Cit60,72,74 bears the major ACPA epitope recognised by the rheumatoid arthritis-specific anticitrullinated fibrinogen autoantibodies and anti-CCP2 antibodies

Annals of the Rheumatic Diseases

Volumn 73, Issue 6, 2014, Pages 1246-1252

  Cornillet, M ^a   Sebbag, M ^a   Verrouil, E ^b,c   Magyar, A ^c   Babos, F ^c   Ruyssen Witrand, A ^b   Hudecz, F ^c   Cantagrel, A ^b   Serre, G ^a,b   Nogueira, L ^a,b  

^a University of Toulouse III   (France)

^b TOULOUSE UNIVERSITY HOSPITAL   (France)

^c EÖTVÖS LORÁND UNIVERSITY   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; FIBRIN; FIBRIN DERIVED CITRULLYL CONTAINING PEPTIDE; FIBRINOGEN; IMMUNOGLOBULIN G ANTIBODY; RHEUMATOID FACTOR; UNCLASSIFIED DRUG;

ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY;

ANT-CCP; AUTOANTIBODIES; AUTOIMMUNITY; B CELLS; RHEUMATOID ARTHRITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CASE-CONTROL STUDIES; CITRULLINE; EPITOPES; FEMALE; FIBRIN; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; HUMANS; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PEPTIDES, CYCLIC; RHEUMATIC DISEASES; RHEUMATOID FACTOR; YOUNG ADULT;

EID: 84899951342     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2012-202868     Document Type: Article

References (36)

1. Klareskog L, Ronnelid J, Lundberg K, et al. Immunity to citrullinated proteins in rheumatoid arthritis. Annu Rev Immunol 2008;26: 651-75. (Pubitemid 351600388)
2. Sebbag M, Clavel C, Nogueira L, et al. Autoimmune response to posttranslationally modified (citrullinated) proteins: prime suspect in the pathophysiology of rheumatoid arthritis. Chichester: John Wiley and Sons, Ltd, 2009;279-308.
3. Nishimura K, Sugiyama D, Kogata Y, et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med 2007;146: 797-808. (Pubitemid 351650500)
4. Girbal-Neuhauser E, Durieux JJ, Arnaud M, et al. The epitopes targeted by the rheumatoid arthritis-associated antifilaggrin autoantibodies are posttranslationally generated on various sites of (pro)filaggrin by deimination of arginine residues. J Immunol 1999;162: 585-94. (Pubitemid 29018970)
5. Schellekens GA, de Jong BA, van den Hoogen FH, et al. Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies. J Clin Invest 1998;101: 273-81. (Pubitemid 28058927)
6. Whiting PF, Smidt N, Sterne JA, et al. Systematic review: accuracy of anti-citrullinated Peptide antibodies for diagnosing rheumatoid arthritis. Ann Intern Med 2010;152:456-64; W155-66.
7. Nielen MM, van Schaardenburg D, Reesink HW, et al. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum 2004;50: 380-6. (Pubitemid 38198821)
8. Forslind K, Ahlmen M, Eberhardt K, et al. Prediction of radiological outcome in early rheumatoid arthritis in clinical practice: role of antibodies to citrullinated peptides (anti-CCP). Ann Rheum Dis 2004;63: 1090-5. (Pubitemid 39120360)
9. Nicaise-Roland P, Nogueira L, Demattei C, et al. Autoantibodies to citrullinated fibrinogen compared with anti-MCV and anti-CCP2 antibodies in diagnosing rheumatoid arthritis at an early stage: data from the French ESPOIR cohort. Ann Rheum Dis 2013;72: 357-62.
10. Neogi T, Aletaha D, Silman AJ, et al. The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. Arthritis Rheum 2010;62: 2582-91.
11. Masson-Bessière C, Sebbag M, Girbal-Neuhauser E, et al. The major synovial targets of the rheumatoid arthritis-specific antifilaggrin autoantibodies are deiminated forms of the alpha- and beta-chains of fibrin. J Immunol 2001;166: 4177-84. (Pubitemid 32224951)
12. Tilleman K, Van Steendam K, Cantaert T, et al. Synovial detection and autoantibody reactivity of processed citrullinated isoforms of vimentin in inflammatory arthritides. Rheumatology 2008;47: 597-604. (Pubitemid 351619196)
13. Kinloch A, Tatzer V, Wait R, et al. Identification of citrullinated alpha-enolase as a candidate autoantigen in rheumatoid arthritis. Arthritis Res Ther 2005;7:R1421-9.
14. Vander Cruyssen B, Cantaert T, Nogueira L, et al. Diagnostic value of anti-human citrullinated fibrinogen ELISA and comparison with four other anti-citrullinated protein assays. Arthritis Res Ther 2006;8:R122.
15. Wernick RM, Lipsky PE, Marban-Arcos E, et al. IgG and IgM rheumatoid factor synthesis in rheumatoid synovial membrane cell cultures. Arthritis Rheum 1985;28: 742-52. (Pubitemid 15027327)
16. Masson-Bessière C, Sebbag M, Durieux JJ, et al. In the rheumatoid pannus, anti-filaggrin autoantibodies are produced by local plasma cells and constitute a higher proportion of IgG than in synovial fluid and serum. Clin Exp Immunol 2000;119: 544-52. (Pubitemid 30146353)
17. Clavel C, Nogueira L, Laurent L, et al. Induction of macrophage secretion of tumor necrosis factor alpha through Fcgamma receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen. Arthritis Rheum 2008;58: 678-88. (Pubitemid 351364865)
18. Sebbag M, Moinard N, Auger I, et al. Epitopes of human fibrin recognized by the rheumatoid arthritis-specific autoantibodies to citrullinated proteins. Eur J Immunol 2006;36: 2250-63. (Pubitemid 44251769)
19. Iobagiu C, Magyar A, Nogueira L, et al. The antigen specificity of the rheumatoid arthritis-associated ACPA directed to citrullinated fibrin is very closely restricted. J Autoimmunity 2011;37: 263-72.
20. Chapuy-Regaud S, Nogueira L, Clavel C, et al. IgG subclass distribution of the rheumatoid arthritis-specific autoantibodies to citrullinated fibrin. Clin Exp Immunol 2005;139: 542-50. (Pubitemid 40333267)
21. McKenzie DP, Vida S, Mackinnon AJ, et al. Accurate confidence intervals for measures of test performance. Psychiatry Res 1997;69: 207-9. (Pubitemid 27146350)
22. Zhang J, Quan H, Ng J, et al. Some statistical methods for multiple endpoints in clinical trials. Control Clin Trials 1997;18: 204-21. (Pubitemid 27277907)
23. Dhandha MM, Seiffert-Sinha K, Sinha AA. Specific immunoglobulin isotypes correlate with disease activity, morphology, duration and HLA association in Pemphigus vulgaris. Autoimmunity 2012;45: 516-26.
24. Bos WH, Bartelds GM, Vis M, et al. Preferential decrease in IgG4 anti-citrullinated protein antibodies during treatment with tumour necrosis factor blocking agents in patients with rheumatoid arthritis. Ann Rheum Dis 2009;68: 558-63.
25. van Beers JJ, Raijmakers R, Alexander LE, et al. Mapping of citrullinated fibrinogen B-cell epitopes in rheumatoid arthritis by imaging surface plasmon resonance. Arthritis Res Ther 2010;12:R219.
26. Hermansson M, Artemenko K, Ossipova E, et al. MS analysis of rheumatoid arthritic synovial tissue identifies specific citrullination sites on fibrinogen. Proteomics Clin Appl 2010;4: 511-18.
27. Ioan-Facsinay A, Willemze A, Robinson DB, et al. Marked differences in fine specificity and isotype usage of the anti-citrullinated protein antibody in health and disease. Arthritis Rheum 2008;58: 3000-8.
28. van der Woude D, Rantapaa-Dahlqvist S, Ioan-Facsinay A, et al. Epitope spreading of the anti-citrullinated protein antibody response occurs before disease onset and is associated with the disease course of early arthritis. Ann Rheum Dis 2010;69: 1554-61.
29. Hansson LM, Schlederer T, Israelsson L, et al. Validation of a multiplex chip-based for the detection of autoantibodies against citrullinated peptides. Arthritis Res Ther. 2012;14:R201.
30. Willemze A, van der Woude D, Ghidey W, et al. The interaction between HLA SE alleles and smoking and its contribution to autoimmunity against several citrullinated antigens. Arthritis Rheum 2011;63: 1823-32.
31. Lundberg K, Kinloch A, Fisher BA, et al. Antibodies to citrullinated alpha-enolase peptide 1 are specific for rheumatoid arthritis and cross-react with bacterial enolase. Arthritis Rheum 2008;58: 3009-19.
32. Anzilotti C, Merlini G, Pratesi F, et al. Antibodies to viral citrullinated peptide in rheumatoid arthritis. J Rheumatol 2006;33: 647-51.
33. Ioan-Facsinay A, el-Bannoudi H, Scherer HU, et al. Anti-cyclic citrullinated peptide antibodies are a collection of anti-citrullinated protein antibodies and contain overlapping and non-overlapping reactivities. Ann Rheum Dis 2010;70: 188-93.
34. van de Stadt LA, van der Horst AR, de Koning MH, et al. The extent of the anti-citrullinated protein antibody repertoire is associated with arthritis development in patients with seropositive arthralgia. Ann Rheum Dis 2011;70: 128-33.
35. Lundberg K, Bengtsson C, Kharlamova N, et al. Genetic and environmental determinants for disease risk in subsets of rheumatoid arthritis defined by the anticitrullinated protein/peptide antibody fine specificity profile. Ann Rheum Dis 2013;72: 652-8.
36. van de Stadt LA, van Schouwenburg PA, Bryde S, et al. Monoclonal anti-citrullinated protein antibodies selected on citrullinated fibrinogen have distinct targets with different cross-reactivity patterns. Rheumatology (Oxford) 2013;52: 631-5.